Search research articles
Contact Us
Filters
Showing results (181-190 of 253) with videos related to
Page
of 26
Sort By:
Nutrients
|
May 27, 2023
Sociodemographic and Health Correlates of Multiple Health Behavior Adherence among Cancer Survivors: A Latent Class Analysis
Angela J Fong, Adana A M Llanos, Adiba Ashrafi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 15, 2009
The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial
Andrew M Evens, William G Spies, Irene B Helenowski, et al.
Cancer
|
August 8, 2013
Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project
Andrew M Evens, Ann Vanderplas, Ann S LaCasce, et al.
Journal of the National Cancer Institute
|
January 2, 2017
Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations
Catherine S Diefenbach, Joseph M Connors, Jonathan W Friedberg, et al.
British Journal of Haematology
|
November 3, 2012
Expression of CD25 independently predicts early treatment failure of acute myeloid leukaemia (AML)
Jan Cerny, Hongbo Yu, Muthalagu Ramanathan, et al.
Blood
|
September 29, 2020
Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma
Pamela B Allen, Hatice Savas, Andrew M Evens, et al.
British Journal of Haematology
|
January 29, 2014
A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era
Peter J Hosein, Jocelyn C Maragulia, Matthew P Salzberg, et al.
British Journal of Haematology
|
May 2, 2023
Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD
Marshall McKenna, Narendranath Epperla, Armin Ghobadi, et al.
British Journal of Haematology
|
October 24, 2006
Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project
Charles L Bennett, Andrew M Evens, Leslie A Andritsos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 1, 2010
Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports
A M Evens, B D Jovanovic, Y-C Su, et al.
Page
of 26
Search research articles
Search
Showing results (181-190 of 253) with videos related to
Sort By:
Page
of 26
Nutrients
|
May 27, 2023
Sociodemographic and Health Correlates of Multiple Health Behavior Adherence among Cancer Survivors: A Latent Class Analysis
Angela J Fong, Adana A M Llanos, Adiba Ashrafi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 15, 2009
The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial
Andrew M Evens, William G Spies, Irene B Helenowski, et al.
Cancer
|
August 8, 2013
Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project
Andrew M Evens, Ann Vanderplas, Ann S LaCasce, et al.
Journal of the National Cancer Institute
|
January 2, 2017
Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations
Catherine S Diefenbach, Joseph M Connors, Jonathan W Friedberg, et al.
British Journal of Haematology
|
November 3, 2012
Expression of CD25 independently predicts early treatment failure of acute myeloid leukaemia (AML)
Jan Cerny, Hongbo Yu, Muthalagu Ramanathan, et al.
Blood
|
September 29, 2020
Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma
Pamela B Allen, Hatice Savas, Andrew M Evens, et al.
British Journal of Haematology
|
January 29, 2014
A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era
Peter J Hosein, Jocelyn C Maragulia, Matthew P Salzberg, et al.
British Journal of Haematology
|
May 2, 2023
Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD
Marshall McKenna, Narendranath Epperla, Armin Ghobadi, et al.
British Journal of Haematology
|
October 24, 2006
Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project
Charles L Bennett, Andrew M Evens, Leslie A Andritsos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 1, 2010
Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports
A M Evens, B D Jovanovic, Y-C Su, et al.
Page
of 26